Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director KISNER DANIEL L
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director CARTER MICHAEL G
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director DeSimone Jill
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director THEUER CHARLES
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HALE DAVID F
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director LARUE WILLIAM R
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wills Robert James
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wills Robert James
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wills Robert James
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HALE DAVID F
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Wills Robert James
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer BREITMEYER JAMES B
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Leavitt Chase C.
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Krishnan Rajesh
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Yazji Salim
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer VINCENT RICHARD G
Oncternal Therapeutics | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Vanguard Group(4.85%)
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer BREITMEYER JAMES B
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Leavitt Chase C.
Oncternal Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Yazji Salim